INSPIREMD, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.265 USD | +1.35% |
|
+6.84% | -19.40% |
| Mar. 06 | Transcript : InspireMD, Inc., Q4 2023 Earnings Call, Mar 06, 2024 | |
| Mar. 06 | Earnings Flash (NSPR) INSPIREMD Posts Q4 Revenue $1.8M | MT |
Presentation Operator MessageOperator (Operator)Greetings, welcome to the InspireMD Third Quar...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
Calendar
2024-05-14
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.235
USD
Average target price
4.5
USD
Spread / Average Target
+101.35%
| 1st Jan change | Capi. | |
|---|---|---|
| -19.40% | 52.35M | |
| -4.77% | 182B | |
| +1.42% | 110B | |
| -3.23% | 68.11B | |
| +1.17% | 50.53B | |
| +9.29% | 44.8B | |
| +2.84% | 40.7B | |
| +21.22% | 32.25B | |
| +2.69% | 26.53B | |
| +15.25% | 25.02B |
- Stock Market
- Equities
- NSPR Stock
- News InspireMD, Inc.
- Transcript : InspireMD, Inc., Q3 2019 Earnings Call, Nov 12, 2019